Abstract
GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins.
| Original language | English |
|---|---|
| Journal | Diabetes Research and Clinical Practice |
| Volume | 82 |
| Issue number | SUPPL. 2 |
| DOIs | |
| Publication status | Published - Dec 15 2008 |
Fingerprint
Keywords
- Diabetes mellitus
- DPP-4 inhibitors
- Exenatide
- GLP-1 analogues
- Sitagliptin
- Vidagliptin
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Internal Medicine
- Endocrinology
Cite this
Incretin-based therapies in type 2 diabetes : A review of clinical results. / Bosi, Emanuele; Lucotti, Pietro; Setola, Emanuela; Monti, Lucilla; Piatti, Pier Marco.
In: Diabetes Research and Clinical Practice, Vol. 82, No. SUPPL. 2, 15.12.2008.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Incretin-based therapies in type 2 diabetes
T2 - A review of clinical results
AU - Bosi, Emanuele
AU - Lucotti, Pietro
AU - Setola, Emanuela
AU - Monti, Lucilla
AU - Piatti, Pier Marco
PY - 2008/12/15
Y1 - 2008/12/15
N2 - GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins.
AB - GLP-1 analogues (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) represent new classes of anti-diabetic agents for the treatment of type 2 diabetes. The efficacy and safety of the incretin mimetic exenatide and of the DPP-4 inhibitors, sitagliptin and vildagliptin, have been clearly demonstrated by a very large number of clinical trials. Efficacy was demonstrated in terms of reduction of HbA1c, fasting and postprandial glucose. Moreover, exenatide showed a favourable effect on weight, while DPP-4 inhibitors were neutral with respect to this outcome. The low rate of hypoglycemic events seen in all studies confirms the glucose dependent action of incretins.
KW - Diabetes mellitus
KW - DPP-4 inhibitors
KW - Exenatide
KW - GLP-1 analogues
KW - Sitagliptin
KW - Vidagliptin
UR - http://www.scopus.com/inward/record.url?scp=56949086428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56949086428&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2008.10.003
DO - 10.1016/j.diabres.2008.10.003
M3 - Article
C2 - 19022515
AN - SCOPUS:56949086428
VL - 82
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
SN - 0168-8227
IS - SUPPL. 2
ER -